The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. - Wikidata - awgldk - TriplyDB

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.

http://www.wikidata.org/entity/Q38210070

about

Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology Molecular classifications of gastric cancers: Novel insights and possible future applications.The up-regulation of miR-300 in gastric cancer and its effects on cells malignancy.Nucleostemin regulates proliferation and migration of gastric cancer and correlates with its malignancy Expression of aurora kinase A correlates with the Wnt-modulator RACGAP1 in gastric cancer.A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2.MicroRNA-126 regulates migration and invasion of gastric cancer by targeting CADM1.MicroRNA let-7b suppresses human gastric cancer malignancy by targeting ING1.Metastatic gastric cancer in the last two decades: goals achieved and future promises.Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis.Knockdown of EGFR inhibits growth and invasion of gastric cancer cells.Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer.Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis.Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.Proposed Molecular and miRNA Classification of Gastric Cancer.Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer

P2860

Q28085398-46FBA34C-748D-4B3C-8E4A-7AFC0BE17763 Q33696201-A25B9E0A-945F-4A2A-94D6-602E9DE9B3D1 Q35870591-3C59E8AA-F757-4662-A9C3-12DE11B5C99D Q36411581-118CD8B3-7132-4221-A7EF-08926A1398F0 Q36706862-9940B129-92D1-4A8B-B617-9F5F1CDDBD3E Q37224355-046F0271-AAFD-4342-80A1-CA0AAC576E20 Q37366255-5895996D-4807-4D25-B91F-19EE1420CB97 Q37708897-0DA409EF-0DC0-4FC5-B225-581DEB89C02D Q38825712-A6FF4DD5-AC81-414F-B7BD-E4C8B7AEEAAD Q38828089-9A17C0B6-EAEC-4010-ADFE-DB125B451AA0 Q38917372-80EA0FEA-A11B-46B4-9C8E-2E8A046DF560 Q38965310-8CD7FFBD-6981-40B5-9647-FB45349FE8E3 Q39061328-0292479B-B43E-4C0C-AF7D-5033BD995D33 Q40543344-2E12B3CC-CA0F-4036-B033-BEC16C3396D7 Q42181490-94ECEC05-1A60-4785-BB2A-CB76D2FAA67A Q51420113-BCB521A1-46FC-4B9E-A759-B6D73CDCDF29 Q52670051-4A94072B-10B9-47D1-80C1-D27BD39F13CB Q53598605-A0695DF6-8E39-4BB4-9CE3-5732F93762B6 Q55603677-961450BE-178B-4A6E-87C2-880079F43E3D Q57167306-84E567C7-0E4D-4154-A47A-71982B1302EE

P2860

The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.

http://www.wikidata.org/entity/Q38210070

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The challenge of targeted ther ...... e beginning of a long journey.

@en

type

label

The challenge of targeted ther ...... e beginning of a long journey.

@en

prefLabel

The challenge of targeted ther ...... e beginning of a long journey.

@en

P1433

Q38210070-0667D9B9-9598-494A-8A54-215F9CC06D3F

P1476

Q38210070-AC266DC6-B3A7-4B58-8261-A9A363548D38

P2093

Q38210070-3AB60405-1EFD-4229-88B9-0D5150F135ED

Q38210070-3C966661-0E84-4BF5-80AA-09592E4AAB0B

Q38210070-5D234735-A3A1-4BB3-9842-A5BE423B75F9

Q38210070-70B18E3B-043D-42DB-8454-9ECCF779E7DB

Q38210070-7EF7F5D9-AFCC-4575-8587-5566FC2E1B47

Q38210070-8FAB97CE-5DF5-46FF-B152-BC2DD1C0CCD3

Q38210070-915B647E-A1AB-4FAF-8DB3-374262635701

Q38210070-E2D8ABE9-E972-47B1-B673-EA847056993B

P2860

Q38210070-0097EAFF-1941-41F3-BE22-B2387A774E29

Q38210070-00CD5125-2E9E-4191-897F-1FBC34767E22

Q38210070-04A69841-EF1F-4DBA-BD54-5FA615AEDBAA

Q38210070-0CAE5D62-2844-4DD7-8B28-30C4F109D24B

Q38210070-0D2BBA46-13F1-4E78-A53E-378C7250AF46

Q38210070-0F3899B9-A3DB-49BD-895B-7B9F4E5F7DA5

Q38210070-119D03D1-647F-4468-88F6-0E3A8E2639B1

Q38210070-1416084F-31EB-4A2C-9715-91CD6B6F449E

Q38210070-16BFEB7C-AEDC-4469-A288-D3B1A202814B

Q38210070-206DA227-499B-40A6-9F3B-27FBC5563B84

P304

Q38210070-575199BC-F12E-491E-9670-B169067FE142

P31

Q38210070-6F8F2F3D-FA7B-4AA1-93BE-534D9B67379B

P356

Q38210070-5091B8A6-21D1-40B4-8660-EB297D575727

P407

Q38210070-A075E87C-1A00-44FE-A8EC-DEF9914AFF43

P433

Q38210070-0A8859CB-4180-4F37-9FBE-74867C1EE7F6

P478

Q38210070-54B2C9B3-2346-4479-B377-2022B9F5F02A

P50

Q38210070-2C413377-DC16-4BAD-862B-0831D7D396BF

Q38210070-440A5654-5F97-4875-9A4D-FB3C6B544E49

Q38210070-83C13794-5707-4895-8CEF-E1EFF3D688C4

P577

Q38210070-ABDC74E1-C126-4C23-B4CB-46C77AE48680

P5875

Q38210070-09A7833E-1A4D-4755-ABBC-43510878366F

P698

Q38210070-70179D35-F348-4223-9FA9-C1A1C734D245

P356

13543784.2014.912631

P1433

Expert Opinion on Investigational Drugs

P1476

The challenge of targeted ther ...... e beginning of a long journey.

@en

P2093

Alessandro Bittoni

http://www.w3.org/2001/XMLSchema#string

Elena Ongaro

http://www.w3.org/2001/XMLSchema#string

Francesco Giuliani

http://www.w3.org/2001/XMLSchema#string

Francesco Graziano

http://www.w3.org/2001/XMLSchema#string

Gianpiero Fasola

http://www.w3.org/2001/XMLSchema#string

Giovanni Gerardo Cardellino

http://www.w3.org/2001/XMLSchema#string

Giuseppe Aprile

http://www.w3.org/2001/XMLSchema#string

Riccardo Giampieri

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Global cancer statistics

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

Targeting the mTOR signaling network for cancer therapy

The genetic basis for cancer treatment decisions

Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

P304

925-942

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.912631

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Cascinu

Mario Scartozzi

P577

2014-05-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262148310

http://www.w3.org/2001/XMLSchema#string

P698

24806575

http://www.w3.org/2001/XMLSchema#string